Holen Sie sich die Stockscreener-App
1.18
0.85%
0.01
Schlusskurs vom Vortag:
$1.17
Offen:
$1.19
24-Stunden-Volumen:
647.09K
Relative Volume:
0.71
Marktkapitalisierung:
$50.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.92M
KGV:
-0.6874
EPS:
-1.7167
Netto-Cashflow:
$-26.53M
1W Leistung:
-9.92%
1M Leistung:
-30.59%
6M Leistung:
-48.25%
1J Leistung:
-47.09%
1-Tages-Spanne:
$1.135
$1.1964
1-Wochen-Bereich:
$1.135
$1.43
52-Wochen-Spanne:
$1.04
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.18 | 55.91M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Uses AI Platform to Accelerate Buntanetap FDA Filing - MyChesCo
Annovis Bio stock reports 862 Phase 3 enrollments - AD HOC NEWS
Annovis Bio Partners With Weave Bio's AI Regulatory Platform in Preparation of NDA for Buntanetap - BioBuzz
Annovis Bio, Inc. Announces Partnership With Weave Bio In Preparation Of NDA For Buntanetap In Alzheimer?s Disease - marketscreener.com
Annovis Bio partners with Weave Bio for NDA preparation By Investing.com - Investing.com Australia
Annovis Bio partners with Weave Bio for NDA preparation - Investing.com
Annovis Announces Partnership with Weave Bio, AI Regulatory - GlobeNewswire
Annovis Bio announces special shareholder meeting - Bitget
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss as Clinical-Stage Company Reports No Revenue - dars.gov.et
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Annovis Bio stock reacts to webinar plan and steep discount to analyst targets - AD HOC NEWS
Annovis Bio Stock Price Forecast. Should You Buy ANVS? - StockInvest.us
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA - TradingView
ANVS: Top-line phase III Alzheimer's data expected in March, with NDA filing and funding plans in place - TradingView
Annovis Bio (ANVS) Edges Higher, Holding Key Support at $1.65Momentum Breakout Ideas - vinanet.vn
Annovis Bio Drops Nearly 5% to $1.72 as Biotech Volatility ResurfacesBearish Pattern Stocks - vinanet.vn
ANVS Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineProfit Announcement - vinanet.vn
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Annovis to Host Corporate Update Webinar on September 2, 2026 - GlobeNewswire
Annovis (ANVS) Results Breakdown: Profit Per Share Falls Below Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
Annovis (ANVS) Range: Slides 2.47% to $1.77 in Latest Trading; Price Setup: the Supplied Trading Band Runs From $1.68 to $1.86 on the DayWave Extension - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) - The Globe and Mail
CCORF Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Annovis Bio (NYSE:ANVS) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Annovis Bio stock price target reiterated at $17 by Canaccord - Investing.com
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Stock Options of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 17-AUG-2026. - marketscreener.com
Annovis Bio (ANVS) Advances 3.35% as Shares Test Key Resistance Near $1.94Volume Profile - vinanet.vn
Annovis Bio (NYSE:ANVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Annovis Bio (ANVS) posts $32.4M loss and warns on going-concern risk - Stock Titan
ANVS: Net loss rose sharply as clinical trial costs surged, with cash runway only through Q4 2026 - TradingView
Annovis Bio | 10-Q: Q2 2026 Earnings Report - Moomoo
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year - tradingview.com
Annovis Reports $14.8 Million Q2 Loss as Phase 3 AD Trial Fully Enrolls - Quiver Quantitative
Highbridge Capital (ANVS) discloses 6.1% Annovis Bio stake tied to 2.78M warrant shares - Stock Titan
Annovis Bio | SCHEDULE 13G: Others - Moomoo
Annovis Bio Sees Unusually Large Options Volume (NYSE:ANVS) - MarketBeat
Annovis Bio Q2 EPS of $(0.40) beats $(0.45) estimate - scanx.trade
Annovis Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - The Manila Times
ANNOVIS BIO Q2 EPS USD -0.4 - Moomoo
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results - Moomoo
Annovis Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Empery Asset Management, LP's Annovis Bio Inc(ANVS) Holding History - GuruFocus
Annovis Bio (ANVS) Holds Ground at $1.79, Testing Critical Support in a Cautious Biotech MarketOn Balance Volume - vinanet.vn
Annovis Bio, Inc. (ANVS) options chain - Yahoo Finance Singapore
Annovis Bio (ANVS) Edges Lower But Holds Above Key Support at $1.78Hagopian Line - careplusvn.com
Annovis Bio Inc (ANVS) Stock News Today - TradingKey
Annovis Bio Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):